Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Appelate Court Upholds AstraZeneca Ruling

By Drug Discovery Trends Editor | April 7, 2010

TRENTON, N.J. (AP) – A federal appellate court has upheld a lower court ruling dismissing the first product liability lawsuit among thousands alleging British drugmaker AstraZeneca PLC’s antipsychotic drug Seroquel triggered a patient’s diabetes.

A three-judge panel of the 11th Circuit Court of Appeals ruled Tuesday that the U.S. District Court for the Middle District of Florida had correctly dismissed the case brought by Linda Guinn, a former legal secretary from Palm Bay, Fla., in her early 60s.

Before that case was to go to trial, AstraZeneca successfully argued in January 2009, before District Judge Anne Conway, that Guinn’s doctor did not qualify as an expert under federal court rules and so her testimony should be excluded. The drugmaker also persuaded the judge to grant a summary judgment motion in its favor, arguing that Guinn failed to establish that Seroquel caused her diabetes.

The 11th Circuit Court, based in Atlanta, upheld those decisions.

“The appeals court decision echoes earlier federal and state court opinions that found Seroquel could not be proven to be responsible for plaintiffs’ alleged injuries,” AstraZeneca spokesman Tony Jewell said in a statement.

Guinn’s physician, Dr. Jennifer Marks, had given the district court an expert opinion stating that her patient gained about 40 pounds over five years while taking Seroquel, which is linked to significant weight gain in many patients, and, as a result, Guinn developed diabetes. AstraZeneca countered that the woman had a strong family history of diabetes and had other risk factors for the blood sugar disorder, including a sedentary lifestyle and high blood pressure and cholesterol.

AstraZeneca, which has its U.S. headquarters in Wilmington, Del., faces more than 25,000 product liability lawsuits over Seroquel, with most alleging that the drug caused diabetes.

The drugmaker has used a similar strategy – questioning expert witness’ qualifications and whether plaintiffs have strong evidence that Seroquel caused their diabetes – to get numerous other lawsuits over the drug dismissed.

Seroquel is approved for treating schizophrenia and bipolar disorder, but is widely prescribed for unapproved uses, including other psychiatric conditions and insomnia. Partly because of all that so-called off-label use, the drug brought in $4.9 billion last year, making it Astra Zeneca’s second-best seller. It’s been on the market since 1997.

Last fall, the company said it had reached a $520 million settlement in principle to end a federal investigation of alleged improper marketing of Seroquel, including promoting it for unapproved uses.

Date: April 6, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE